Presentation is loading. Please wait.

Presentation is loading. Please wait.

Disease activity as measured by British Isles Lupus Assessment Group (BILAG) responder analysis in different groups. Disease activity as measured by British.

Published byMuzio Luciani Modified over 5 years ago

Similar presentations

Presentation on theme: "Disease activity as measured by British Isles Lupus Assessment Group (BILAG) responder analysis in different groups. Disease activity as measured by British."— Presentation transcript:

1 Disease activity as measured by British Isles Lupus Assessment Group (BILAG) responder analysis in different groups. Disease activity as measured by British Isles Lupus Assessment Group (BILAG) responder analysis in different groups. (A) BILAG responder analysis at Last Office Visit (LOV) versus Baseline predefined analysis on intention to treat (ITT) cohort (0.5 mg arm n=76; Placebo arm n-83). (B) BILAG responder analysis of patients receiving steroids <20 mg/day at baseline (0.5 mg arm n=68; Placebo arm n=69). (C) BILAG responder analysis of seropositive patients (anti-DNA>30 IU at baseline) (0.5 mg arm n=26; Placebo arm n=31). Murray B Urowitz et al. Lupus Sci Med 2015;2:e000104 ©2015 by Lupus Foundation of America

Download ppt "Disease activity as measured by British Isles Lupus Assessment Group (BILAG) responder analysis in different groups. Disease activity as measured by British."

Similar presentations

Study Trial design No. of patients Randomisation Outcomes assessed

Study Trial design No. of patients Randomisation Outcomes assessed
Proportion of patients that met the SRI-5 response criteria (A and C) and reasons for non-response (B and D) in trial 1 (A and B) and trial 2 (C and D).

Proportion of patients that met the SRI-5 response criteria (A and C) and reasons for non-response (B and D) in trial 1 (A and B) and trial 2 (C and D).
Baseline Characteristics of the Patients Part I

Baseline Characteristics of the Patients Part I
Effects of MMF treatment in patients with SLE

Effects of MMF treatment in patients with SLE
EULAR Lupus Nephritis Trials Network Study Group 2017

EULAR Lupus Nephritis Trials Network Study Group 2017
Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45:380-388 (DOI:

Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45: (DOI:
Placebo group 5-mg rimonabant group p 20-mg rimonabant group

Placebo group 5-mg rimonabant group p 20-mg rimonabant group
Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.

Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.
Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.

Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.
ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,

ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.

Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.
Correlation between disease activity and phospho-H2AX levels at G0/G1, S and G2 cell-cycle phases in primary CD3+ T cells and monocytes from patients with.

Correlation between disease activity and phospho-H2AX levels at G0/G1, S and G2 cell-cycle phases in primary CD3+ T cells and monocytes from patients with.
FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.
Fig. 1. MAHALO clinical trial flowchart.

Fig. 1. MAHALO clinical trial flowchart.
Mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at the last.

Mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at the last.
Immunohistochemistry staining of interferon (IFN)-λ in renal tissue.

Immunohistochemistry staining of interferon (IFN)-λ in renal tissue.
Study design (A) and subject disposition (B).

Study design (A) and subject disposition (B).
HAQ-DI change from baseline and proportion of patients achieving MCID after 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination.

HAQ-DI change from baseline and proportion of patients achieving MCID after 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination.
Lupus Foundation of America-Rapid Evaluation of Activity in Lupus (LFA-REAL) comprised seven anchored Visual Analogue Scales (0–100 mm each) and can describe.

Lupus Foundation of America-Rapid Evaluation of Activity in Lupus (LFA-REAL) comprised seven anchored Visual Analogue Scales (0–100 mm each) and can describe.

Similar presentations

Ads by Google